The adenocarcinoma subset of NSCLC (lung adenocarcinoma (LUAD)) includes patients with EGFR activating mutations, the prevalence of which ranges from 15% in Western populations to up to 50% in Asian populations [30]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.